PMID- 35864467
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220725
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jul 21
TI  - Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) 
      regimen with or without targeted drugs in patients with metastatic colorectal 
      cancer: a retrospective cohort study.
PG  - 807
LID - 10.1186/s12885-022-09889-3 [doi]
LID - 807
AB  - BACKGROUND: Five-fluorouracil, folinic acid, oxaliplatin and irinotecan 
      (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal 
      cancer (mCRC). The use of capecitabine, an oral fluoropyrimidine pro-drug, is 
      feasible and safe; hence, it provides an interesting alternative to 
      5-fluorouracil in the abovementioned regimen. This study aimed to evaluate the 
      efficacy and safety of capecitabine, oxaliplatin, and irinotecan (XELOXIRI) 
      regimen use with or without targeted drugs in Chinese patients with mCRC. 
      METHODS: We conducted a retrospective, longitudinal cohort study of patients with 
      mCRC who received XELOXIRI regimen with or without targeted drugs (bevacizumab or 
      cetuximab) every 2 weeks between January 2017 and November 2019 at the National 
      Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences, and 
      Peking Union Medical College. Treatment efficacy was assessed by investigators by 
      evaluating the objective response rate (ORR) and disease control rate (DCR). 
      Overall survival (OS) was assessed using Cox proportional hazards models. The 
      adverse events were also analyzed. RESULTS: Sixty-one consecutive patients were 
      examined and followed up for survival. As of November 8, 2021, the median 
      follow-up time was 35.4 months. Disease progression and death occurred in 50 
      (82%) and 38 (62%) patients, respectively. The median treatment duration of 
      XELOXIRI with or without bevacizumab or cetuximab was 10 cycles (range, 1-12 
      cycles). The median OS and PFS were 32.2 months (95%CI [24.8-39.6]) and 
      9.3 months (95% CI [8.1-10.5]), respectively. The ORR of 48 patients with 
      measurable lesions was 70.8%, and the DCR was 89.6%. RAS/BRAF wild-type (HR 0.39; 
      95% CI [0.16-0.96], p = 0.04) and metastatic organs > 2 (HR 3.25; 95% CI 
      [1.34-7.87], p = 0.009) were independent prognostic factors for OS. The incidence 
      of any grade of adverse events (AEs) was 96.7% (59/61). Grade >/= 3 AEs included 
      neutropenia (19.7%), leukopenia (9.8%), diarrhea (3.3%), vomiting (3.3%), febrile 
      neutropenia (1.6%), and thrombocytopenia (1.6%). No treatment-related death 
      occurred. CONCLUSION: The use of the XELOXIRI regimen with or without a targeted 
      drug was effective, with a manageable toxicity profile in Chinese patients with 
      mCRC.
CI  - (c) 2022. The Author(s).
FAU - Liu, Xiu
AU  - Liu X
AUID- ORCID: 0000-0001-8993-013X
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No.17 Panjiayuannanli, Beijing, 100021, China.
FAU - Ou, Kai
AU  - Ou K
AUID- ORCID: 0000-0003-2762-6719
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No.17 Panjiayuannanli, Beijing, 100021, China.
FAU - Ma, Xiaoting
AU  - Ma X
AUID- ORCID: 0000-0003-1329-9761
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No.17 Panjiayuannanli, Beijing, 100021, China.
FAU - Gao, Lizhen
AU  - Gao L
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No.17 Panjiayuannanli, Beijing, 100021, China.
AD  - Department of Medical Oncology, Beijing Chaoyang Huanxing Cancer Hospital, 
      Beijing, 100023, China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No.17 Panjiayuannanli, Beijing, 100021, China.
AD  - Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer 
      Hospital, Beijing, 100122, China.
FAU - Zhang, Haizeng
AU  - Zhang H
AD  - Department of Colorectal Surgery, State Key Laboratory of Molecular Oncology, 
      National Cancer Center/National Clinical Research Center for Cancer/Cancer 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      No.17 Panjiayuannanli, Beijing, 100021, China.
FAU - Yang, Lin
AU  - Yang L
AUID- ORCID: 0000-0001-5049-7519
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No.17 Panjiayuannanli, Beijing, 100021, China. 
      linyangcicams@126.com.
LA  - eng
PT  - Journal Article
DEP - 20220721
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - 7673326042 (Irinotecan)
RN  - PQX0D8J21J (Cetuximab)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Bevacizumab/adverse effects
MH  - Camptothecin
MH  - Capecitabine/adverse effects
MH  - Cetuximab/adverse effects
MH  - *Colonic Neoplasms/drug therapy
MH  - *Colorectal Neoplasms/pathology
MH  - Fluorouracil
MH  - Humans
MH  - Irinotecan/therapeutic use
MH  - Leucovorin
MH  - Longitudinal Studies
MH  - Organoplatinum Compounds
MH  - Oxaliplatin/therapeutic use
MH  - *Rectal Neoplasms/drug therapy
MH  - Retrospective Studies
PMC - PMC9306070
OTO - NOTNLM
OT  - Capecitabine
OT  - Colorectal cancer
OT  - Irinotecan
OT  - Oxaliplatin
OT  - Triplet chemotherapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as competing 
      interests.
EDAT- 2022/07/22 06:00
MHDA- 2022/07/26 06:00
PMCR- 2022/07/21
CRDT- 2022/07/21 23:36
PHST- 2022/02/20 00:00 [received]
PHST- 2022/07/04 00:00 [accepted]
PHST- 2022/07/21 23:36 [entrez]
PHST- 2022/07/22 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
PHST- 2022/07/21 00:00 [pmc-release]
AID - 10.1186/s12885-022-09889-3 [pii]
AID - 9889 [pii]
AID - 10.1186/s12885-022-09889-3 [doi]
PST - epublish
SO  - BMC Cancer. 2022 Jul 21;22(1):807. doi: 10.1186/s12885-022-09889-3.